Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma - Related Studies

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

This study is currently recruiting participants.

Study NCT00602641. Last updated on November 26, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Additional conditions recognized in this trial
		Multiple Myeloma
		Neoplasms, Plasma Cell

2	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

3	Interventions listed in this trial
		lenalidomide
		melphalan
		prednisone
		thalidomide

4	More general drug interventions related to this trial
		Alkylating Agents
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Bacterial Agents
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antineoplastic Agents, Hormonal
		Glucocorticoids
		Growth Inhibitors
		Growth Substances
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Leprostatic Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

5	Sponsors listed in this trial
		Eastern Cooperative Oncology Group
		National Cancer Institute (NCI)